REG - Physiomics PLC - Contract Award

PhysiomicsAnnouncement

16/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250716:nRSP1715Ra&default-theme=true

RNS Number : 1715R  Physiomics PLC  16 July 2025

16 July 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded New Contract by Numab Therapeutics

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a new contract with
its valued and long-standing client, Numab Therapeutics AG.

This project will use PK/PD modelling and simulation approaches to inform
understanding and selection of appropriate clinical dosing for a First In
Human ("FiH") study for an antibody in Numab Therapeutics' Inflammation
pipeline. The work for this project is expected to begin imminently and is
expected to complete within the next six months.

This project represents another important step in our ongoing collaboration
applying Model Informed Drug Development ("MIDD") to support a data-driven
approach to drug development and in this case FiH dose selection.

Dr Peter Sargent, CEO of Physiomics, commented:

"We're delighted to be deepening our existing relationship with Numab
Therapeutics through this new project. Applying our MIDD expertise to support
early clinical development aligns perfectly with our mission to help clients
make smarter, faster decisions that can help de-risk development and improve
outcomes. We are also pleased to be supporting the development of a therapy
targeting inflammation, demonstrating our service expansion beyond oncology."

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTGPUBPMUPAGCA